We recently compiled a list of the 10 Worst Performing NASDAQ Stocks in 2024. In this article, we are going to take a look at ...
Prothena Corporation plc's stock has dropped 67% since my last “Buy” rating, primarily due to delays and a lack of meaningful ...
Neurophet to host Symposium featuring renowned expert in Alzheimer's disease treatment from the U.S.
Neurophet has specialized in developing solutions for diagnosis support, treatment guides, and treatment devices targeting ...
Eli Lilly is making a series of investments in China to support its manufacturing and R&D operations. Gilead Sciences has ...
Medicare could save millions of dollars every year by changing the way they package Alzheimer's medication.
New research suggests that Medicare could save up to 74 percent of the money lost from discarded Alzheimer's drug Leqembi or ...
A simple tweak in available vial sizes of the breakthrough Alzheimer's drug Leqembi could save Medicare hundreds of millions ...
An estimated $133 million to $336 million worth of lecanemab may be discarded every year. Adding a 75-mg vial could save ...
A simple tweak in available vial sizes of the breakthrough Alzheimer's drug Leqembi could save Medicare hundreds of millions ...
Since Leqembi is dosed based on a patient’s weight and offered in single-use vials, about 5.8% of the drug dispensed will be ...
Lecanemab (Leqembi; Eisai/Biogen) received traditional approval from the FDA in July 2023, following an accelerated approval ...
Biogen Inc. (NASDAQ:BIIB), a leading biotechnology company focused on neurological and neurodegenerative diseases, finds itself at a critical juncture as it navigates the launch of its Alzheimer's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback